Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 8/20 | 0.63 |
| ▸ | GNAI3 | P08754 | 7/20 | 0.63 |
| ▸ | GNAI1 | P63096 | 7/20 | 0.63 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.63 |
| ▸ | GUSB | P08236 | 2/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1891298 | 1.00 | GNAO1 (0.63) | GNAO1GNAI3GNAI1SPHK1GUSB | |
| SCHEMBL19603949 | 1.00 | GNAO1 (0.63) | GNAO1GNAI3GNAI1SPHK1GUSB | |
| SCHEMBL19275229 | 1.00 | GNAO1 (0.63) | GNAO1GNAI3GNAI1SPHK1GUSB | |
| SCHEMBL4250726 | 0.98 | GNAO1 (0.60) | GNAO1GNAI3GNAI1SPHK1GUSB | |
| SCHEMBL1698806 | 0.91 | SPHK1 (0.57) | GNAO1GNAI3GNAI1SPHK1GUSB | |
| SCHEMBL8637857 | 0.89 | SPHK1 (0.54) | GNAO1GNAI3GNAI1SPHK1GUSB | |
| SCHEMBL8637850 | 0.89 | SPHK1 (0.54) | GNAO1GNAI3GNAI1SPHK1GUSB | |
| Methane SCHEMBL7423590 | 0.89 | SPHK1 (0.56) | GNAO1GNAI3GNAI1SPHK1GUSB | |
| SCHEMBL23168823 | 0.88 | GUSB (0.56) | GNAO1GNAI3GNAI1SPHK1GUSB | |
| SCHEMBL21161002 | 0.88 | GUSB (0.56) | GNAO1GNAI3GNAI1SPHK1GUSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230320995-A1 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES | CAPSTAN THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-11718641-B2 | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-10752598-B2 | Aryldiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-10738042-B2 | Phosphonamidates that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer | UNITY BIOTECHNOLOGY, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-10736904-B2 | Thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof | SANOFI (FR) | 2020-08-11 | — | — | US | disclosed |
| US-20190330199-A1 | Phosphonamidates that are Bcl Family Antagonists for Use in Clinical Management of Conditions Caused or Mediated By Senescent Cells and for Treating Cancer | UNITY BIOTECHNOLOGY, INC. | 2019-10-31 | — | — | US | disclosed |
| US-9216999-B2 | Substituted pyrrolo[2,3-h][1,6]naphthyridines and compositions thereof as JAK inhibitors | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2015-12-22 | — | — | US | disclosed |
| EP-1121355-B1 | QUINOLINE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM PLC (GB) | 2005-12-14 | — | — | EP | disclosed |
| US-6602882-B1 | Quinoline derivatives and their use as antibacterial agents | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-08-05 | — | — | US | disclosed |
| EP-1121355-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM PLC (GB) | 2001-08-08 | — | — | EP | disclosed |
| WO-2000021952-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM PLC (GB) | 2000-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190330199-A1 | Phosphonamidates that are Bcl Family Antagonists for Use in Clinical Management of Conditions Caused or Mediated By Senescent Cells and for Treating Cancer | BAX, BCL2, TP53 | GNAO1 684/4885GNAI3 2425/4885GNAI1 2295/4885 |
| US-20230320995-A1 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES | PLTP, LNPEP, PLIN3 | GNAO1 2211/4885GNAI3 1283/4885GNAI1 1986/4885 |
| US-10752598-B2 | Aryldiazepine derivatives as RSV inhibitors | AHR, FURIN, CYP3A5 | GNAO1 2384/4885GNAI3 1118/4885GNAI1 897/4885 |
| US-10736904-B2 | Thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof | DPYD, TYMP, DHFR | GNAO1 776/4885GNAI3 1387/4885GNAI1 779/4885 |
| US-11718641-B2 | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof | GPBAR1, NR1H4, SLC10A1 | GNAO1 270/4885GNAI3 280/4885GNAI1 254/4885 |
| US-10738042-B2 | Phosphonamidates that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer | BAX, BCL2, TP53 | GNAO1 481/4885GNAI3 2266/4885GNAI1 1815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.